Cycloalkyl Phenylhexanamide Mitofusin Activators for Neurological Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new compounds that target mitofusins to address mitochondrial dysfunction associated with neurodegenerative diseases, as aberrant mitofusin activity contributes to these conditions and existing treatments are inadequate.
Innovation Solution
Development of N-(cycloalkyl or heterocycloalkyl)-6-phenylhexanamide compounds, specifically those with a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl variant, which act as potent mitofusin activators, improving plasma half-life and neurological bioavailability while maintaining high mitofusin activation capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If existing mitofusin targeting compounds are used, then mitofusin activation capability is achieved, but plasma half-life and neurological bioavailability are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of mitofusin activator compounds, specifically varying the cycloalkyl ring size (cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl) and substituent patterns to optimize both plasma half-life and mitofusin activation capability. This structural parameter optimization resolves the contradiction by achieving extended duration of action while maintaining therapeutic effectiveness.
2Duration of action of moving object
If compound structure is modified to improve plasma half-life, then duration of action is extended, but mitofusin activation capability may be reduced
Solution Approach 1:
The patent systematically varies structural parameters including cycloalkyl ring size (3-6 membered rings), substituent types (halogen, hydroxyl, amino, alkyl groups), and their positions to simultaneously optimize plasma half-life and mitofusin activation capability. This multi-parameter optimization approach resolves the contradiction by identifying compound configurations that achieve both extended duration and high productivity.
Solution Approach 2:
The patent applies local quality by introducing specific functional group substitutions at particular positions on the cycloalkyl ring and phenylhexanamide core structure. These localized structural modifications allow independent optimization of pharmacokinetic properties (plasma half-life) and pharmacodynamic properties (mitofusin activation), resolving the contradiction between duration and productivity.
3Reliability
If new compound variants are developed to improve neurological bioavailability, then blood-brain permeability is enhanced, but structural complexity increases
Solution Approach 1:
The patent optimizes neurological bioavailability by systematically varying structural parameters such as cycloalkyl ring size, substituent types, and their positions. This parameter optimization enhances blood-brain permeability while managing structural complexity through systematic rather than random modifications.
Solution Approach 2:
The patent achieves multi-functionality by designing cycloalkyl-substituted phenylhexanamide compounds that simultaneously provide mitofusin activation, extended plasma half-life, and improved neurological bioavailability. This universal design approach resolves the contradiction by making the compound structure serve multiple therapeutic functions without proportionally increasing complexity.
Data Source
AI summary
The present disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing diseases, disorders, or conditions (e.g., associated with mitochondria).